Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.
Frontiers in Medicine · 2025-01-01 · Meta-analysis
Abstract
BACKGROUND: As an anti-fibrinolytic agent, tranexamic acid (TXA) is widely recognized for its efficacy in managing hemorrhagic conditions. Prehospital application of TXA has been reported in recent years, but its benefits in trauma patients remain debated. MATERIALS AND METHODS: A literature search was conducted across databases including PubMed, Cochrane Library, Embase, Web of Science, SCOPUS, and the Cochrane Central Register for Clinical Trials from inception to October 2024, focusing on studies related to prehospital TXA and clinical outcomes in trauma patients. The Cochrane Risk of Bias 2 Tool was applied to assess the quality of randomized control trials (RCTs), while the Newcastle-Ottawa Scale was used for observational cohort studies. Data were pooled under a random- or fixed-effects model using RevMan 5.4 with odds ratio (OR) and 95% confidence interval (CI) as the effect measures. RESULTS: A total of 286 publications were identified from the initial database search, and 12 studies, including five RCTs and seven observational cohort studies with a total of 12,682 patients, were included. Significant early survival benefits were observed in patients receiving prehospital TXA compared to those not receiving prehospital treatment. Compared to the control group, the prehospital TXA group exhibited a significant reduction in 24-h mortality with an OR of 0.72 and a 95% CI of 0.54-0.94 (p = 0.02), while no statistically significant difference in the incidence of venous thromboembolism (VTE; OR: 1.14, 95% CI: 0.98-1.33, p = 0.09). No significant differences were observed in other outcomes, such as 28-30-day mortality, overall mortality, length of hospital stay, and the incidence of multiple organ failure (all p > 0.05). CONCLUSION: Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/, Identifier: CRD 42019132189.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Haemostatics · Mortality & survival · Tranexamic acid
Related articles
- Clinical outcomes of hemostatic interventions in patients with traumatic injury: A systematic review of randomized controlled trials. (J Trauma Acute Care Surg, 2026)
- Comparative efficacy of prehospital resuscitation strategies on mortality for patients with major trauma: a network meta-analysis. (Eur J Emerg Med, 2026)
- The use of tranexamic acid in the management of injured patients at risk of hemorrhage: a systematic review and meta-analysis and an Eastern Association for the Surgery of Trauma Practice Management Guideline. (J Trauma Acute Care Surg, 2025)
- Tranexamic acid in trauma: A joint position statement and resource document of NAEMSP, ACEP, and ACS-COT. (J Trauma Acute Care Surg, 2025)
- Effect of tranexamic acid on children with traumatic bleeding: A systematic review and meta-analysis. (Am J Emerg Med, 2025)
- Inhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries - a systematic review and clinical practice guideline update. (Eur J Trauma Emerg Surg, 2025)